MAPT and Alzheimer disease: They aretargeted by many novel drugs and therapeutics currently under clinicaltrials, which aim to reduce Aβ production, increase the Aβclearance, and inhibit the phosphorylation of tau protein.3 However, the presence of Aβ and NFTs isnot sufficient to fully explain the pathology of AD, indicating theyare only pieces of the AD puzzle.4,5